

# 6/KT
3/4

026.00231 A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: O'Brien et al.)
Serial No.: 09/846,506) Examiner: J. Schultz
Filed: May 1, 2001) Art Unit: 1635
For: USE OF CD63 INHIBITORS)

RECEIVED

FEB 27 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT

Sir:

In response to the August 13, 2002 office action,
please amend the above-identified patent application as
follows:

In the claims:

Please amend claim 5 as follows:

A
5. (Amended) A method of treating human immunodeficiency virus infection in a subject, the method comprising administering to the subject an amount of a compound effective to decrease levels of functional CD63 in cells of the subject.

REMARKS

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

The rejection of claims 1-10 under 35 U.S.C. § 112 (first paragraph) for lack of written description is respectfully traversed.

The basis for the U.S. Patent and Trademark Office's ("PTO") rejection of the claims is that the present